NEW YORK, May 16 – Merck’s acquisition of Rosetta Inpharmatics will not affect the alliance between Rosetta and Agilent Technologies, an exclusive distributor of the Rosetta Resolver gene expression system, Merck and Agilent said Wednesday.

Following Merck’s acquisition of Rosetta, Agilent will continue to work with Rosetta as the only outside distributor of Rosetta Resolver, and will continue to work with Rosetta to develop gene expression technologies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.